| A | |
|---|---|
| Atrican |  |
| B | |
| Biseptol | |
| Boric Acid | |
| C | |
| Chlorhexidine | |
| Corsodyl Mint | |
| D | |
| Decaris | |
| Delagil | |
| E | |
| Efisol | |
| Eskazole | |
| F | |
| Fasigyn | |
| Furacilin | |
| H | |
| Helmintox | |
| K | |
| Klion | |
| L | |
| Lysobact | |
| M | |
| Metrogil Denta | |
| Metrozol | |
| N | |
| Naxogin | |
| Nittyfor | |
| O | |
| Otinum | |
| Otizol | |
| P | |
| Plaquenil | |
| S | |
| Sebidin | |
| Stomatidin | |
| T | |
| Tiberal | |
| Trichopol | |
| V | |
| Vermox | |
| Z | |
| Zentel | |
Juvisync receives an FDA approval
US Food and Drug Administration USA (FDA) approves Juvisync - first combined product for patients with type 2 diabetes and high cholesterol.
Oral contraceptives containing drospirenone: a potentially increased risk of blood clots.
US Food and Drug Administration USA (FDA) continues to study the safety of oral contraceptives containing drospirenone, in terms of the risk of blood clots.
Microgynon Therapeutic Effects
Microgynon is a low dosed monophasic gestogen-estrogen oral contraceptive drug
